Baird lowered the firm’s price target on Zimmer Biomet (ZBH) to $92 from $100 and keeps a Neutral rating on the shares. The firm updated its model ahead of Q1 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $95 from $98 at Citi
- Zimmer Biomet price target lowered to $105 from $120 at Citizens
- Zimmer Biomet price target lowered to $94 from $100 at Barclays
- Zimmer Biomet Earnings Call: Tech Momentum, Higher Guidance
- Analyst Maintains Buy on Zimmer Biomet, Keeps $109 Price Target Amid Ongoing Multi-Year Transformation